Advanced search
Publication Cover
European Clinical Respiratory Journal Volume 9, 2022 - Issue 1
Submit an article Journal homepage
4,655
Views
3
CrossRef citations to date
0
Altmetric
Review Article

Eosinophilic airway diseases: basic science, clinical manifestations and future challenges

Christer Jansona Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5093-6980View further author information
ORCID Icon,
Leif Bjermerb Department of Respiratory Medicine and Allergology, Skane University Hospital, Lund, SwedenView further author information
,
Lauri Lehtimäkic Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland;d Allergy Centre, Tampere University Hospital, Tampere, FinlandORCID Iconhttps://orcid.org/0000-0003-1586-4998View further author information
ORCID Icon,
Hannu Kankaanrantac Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland;e Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden;f Department of Respiratory Medicine, Seinäjoki Central Hospital, Seinäjoki, FinlandORCID Iconhttps://orcid.org/0000-0001-5258-0906View further author information
ORCID Icon,
Jussi Karjalainenc Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland;d Allergy Centre, Tampere University Hospital, Tampere, FinlandView further author information
,
Alan Altrajag Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, EstoniaView further author information
,
Valentyna Yasinskah Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Huddinge, SwedenView further author information
,
Bernt Aarlii Department of Clinical Science, University of Bergen and Department of Thoracic Medicine, Haukeland University Hospital, Bergen, NorwayView further author information
,
Madeleine Rådingere Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, SwedenView further author information
,
Johan Hellgrenj Department of Otorhinolaryngology, University of Gothenburg, Gothenburg, SwedenView further author information
,
Magnus Lofdahlk Respiratory Medical Affairs, GSK, Solna, SwedenView further author information
,
Peter H Howarthl Respiratory Medical Franchise, GSK, Brentford, Middlesex, UKView further author information
&
Celeste Porsbjergm Department of Respiratory Medicine, Bispebjerg Hospital and Copenhagen University, Copenhagen, DenmarkView further author information
 show all
Article: 2040707 | Received 08 Nov 2021, Accepted 07 Feb 2022, Published online: 02 Mar 2022

References

  • Leru PM. Eosinophilic disorders: evaluation of current classification and diagnostic criteria, proposal of a practical diagnostic algorithm. Clin Transl Allergy. 2019;9(1):1–16.
  • Maret-Ouda J, Tao W, Wahlin K, et al. Nordic registry-based cohort studies: possibilities and pitfalls when combining Nordic registry data. Scand J Public Health. 2017;45(17_suppl):14–19.
  • Long H, Liao W, Wang L, et al. A player and coordinator: the versatile roles of eosinophils in the immune system. Transfusion Med Hemotherapy. 2016;43(2):96–108.
  • Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9–22.
  • Samitas K, Radinger M, Bossios A. Current update on eosinophilic lung diseases and anti-IL-5 treatment. Recent Pat Antiinfect Drug Discov. 2011;6(3):189–205.
  • Sehmi R, Smith SG, Kjarsgaard M, et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clin Exp Allergy. 2016;46(6):793–802.
  • Mjosberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016;138(5):1265–1276.
  • Boberg E, Johansson K, Malmhall C, et al. Interplay between the il-33/st2 axis and bone marrow Ilc2s in protease allergen-induced il-5-dependent eosinophilia. Front Immunol. 2020;11:1058.
  • Johansson K, Malmhall C, Ramos-Ramirez P, et al. Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia. Immunology. 2018;153(2):268–278.
  • Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.
  • Kanda A, Yun Y, Bui DV, et al. The multiple functions and subpopulations of eosinophils in tissues under steady-state and pathological conditions. Allergol Int. 2021;70(1):9–18.
  • Coden ME, Berdnikovs S. Eosinophils in wound healing and epithelial remodeling: is coagulation a missing link? J Leukoc Biol. 2020;108(1):93–103.
  • Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279–3295.
  • Abdala Valencia H, Loffredo LF, Misharin AV, et al. Phenotypic plasticity and targeting of Siglec-F(high) CD11c(low) eosinophils to the airway in a murine model of asthma. Allergy. 2016;71(2):267–271.
  • Sastre B, Rodrigo-Munoz JM, Garcia-Sanchez DA, et al. Eosinophils: old players in a new game. J Investig Allergol Clin Immunol. 2018;28(5):289–304.
  • Jacobsen EA, Jackson DJ, Heffler E, et al. Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies. Annu Rev Immunol. 2021;39:719–757.
  • Lee JJ, Jacobsen EA, McGarry MP, et al. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy. 2010;40(4):563–575.
  • Kalinauskaite-Zukauske V, Januskevicius A, Janulaityte I, et al. Expression of eosinophil beta chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma. BMC Pulm Med. 2019;19(1):158.
  • Shult PA, Lega M, Jadidi S, et al. The presence of hypodense eosinophils and diminished chemiluminescence response in asthma. J Allergy Clin Immunol. 1988;81(2):429–437.
  • Miyasato M, Tsuda S, Nakama T, et al. Serum levels of eosinophil cationic protein reflect the state of in vitro degranulation of blood hypodense eosinophils in atopic dermatitis. J Dermatol. 1996;23(6):382–388.
  • Conesa A, Tassinari P, Rivera H, et al. Hypodense eosinophils: characterization of surface molecule expression. Paper presented at: Allergy and asthma proceedings 2002.
  • Marichal T, Mesnil C, Bureau F. Homeostatic eosinophils: characteristics and functions. Front Med (Lausanne). 2017;4:101.
  • Yousefi S, Gold JA, Andina N, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med. 2008;14(9):949–953.
  • Grozdanovic MM, Doyle CB, Liu L, et al. Charcot-Leyden crystal protein/galectin-10 interacts with cationic ribonucleases and is required for eosinophil granulogenesis. J Allergy Clin Immunol. 2020;146(2):377–389 e310.
  • Drake MG, Bivins-Smith ER, Proskocil BJ, et al. Human and mouse eosinophils have antiviral activity against parainfluenza virus. Am J Respir Cell Mol Biol. 2016;55(3):387–394.
  • Rosenberg HF. Recombinant human eosinophil cationic protein: RIBONUCLEASE ACTIVITY IS NOT ESSENTIAL FOR CYTOTOXICITY(*). J Biol Chem. 1995;270(14):7876–7881.
  • Domachowske JB, Dyer KD, Bonville CA, et al. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis. 1998;177(6):1458–1464.
  • Wen T, and Rothenberg ME. The Regulatory Function of Eosinophils. Microbiol Spectr. 2016;4(5). DOI:10.1128/microbiolspec.MCHD-0020-2015
  • Mawhorter SD, Kazura JW, Boom WH. Human eosinophils as antigen-presenting cells: relative efficiency for superantigen- and antigen-induced CD4+ T-cell proliferation. Immunology. 1994;81(4):584–591.
  • Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. 2018;7(2):e1393134.
  • Loktionov A. Eosinophils in the gastrointestinal tract and their role in the pathogenesis of major colorectal disorders. World J Gastroenterol. 2019;25(27):3503–3526.
  • Brigger D, Riether C, van Brummelen R, et al. Eosinophils regulate adipose tissue inflammation and sustain physical and immunological fitness in old age. Nat Metab. 2020;2(8):688–702.
  • Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–150.
  • Wu D, Molofsky AB, Liang HE, et al. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science. 2011;332(6026):243–247.
  • Liu CL, Liu X, Zhang Y, et al. Eosinophils protect mice from angiotensin-II perfusion-induced abdominal aortic aneurysm. Circ Res. 2021;128(2):188–202.
  • Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800.
  • Jakiela B, Szczeklik W, Plutecka H, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford). 2012;51(10):1887–1893.
  • Vedel-Krogh S, Fallgaard Nielsen S, Lange P, et al. Association of blood eosinophil and blood neutrophil counts with asthma exacerbations in the copenhagen general population study. Clin Chem. 2017;63(4):823–832.
  • Hartl S, Breyer MK, Burghuber OC, et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020;55(5):1901874.
  • Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.
  • Kankaanranta H, Lindsay MA, Giembycz MA, et al. Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol. 2000;106(1 Pt 1):77–83.
  • Zhang X, Moilanen E, Kankaanranta H. Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000;406(3):325–332.
  • Zhang X, Moilanen E, Adcock IM, et al. Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002;71(13):1523–1534.
  • Coden ME, Walker MT, Jeong BM, et al. Beyond Il-5: metabolic reprogramming and stromal support are prerequisite for generation and survival of long-lived eosinophil. Cells. 2021;10(4):815.
  • Kankaanranta H, Ilmarinen P, Zhang X, et al. Tumour necrosis factor-alpha regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-kappaB and AP-1. PLoS One. 2014;9(2):e90298.
  • Ilmarinen P, Moilanen E, Erjefalt JS, et al. The polyamine spermine promotes survival and activation of human eosinophils. J Allergy Clin Immunol. 2015;136(2):482–484 e411.
  • Food and Drug Administration. Fasenra (benralizumab) highlights of prescribing information. 2021; https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/3647bed4-ce91-4fe7-9bc5-32dbee73f80a/3647bed4-ce91-4fe7-9bc5-32dbee73f80a_viewable_rendition__v.pdf.
  • Food and Drug Administration. Dupixent (dupilumab) highlights of prescribing information. 2019; https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s012lbl.pdf.
  • Food and Drug Administration. Nucala (mepolizumab) highlights of prescribing information. 2021; https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL-IFU-COMBINED.PDF.
  • Food and Drug Administration. Xolair (omalizumab) highlights of prescribing information. 2020; https://www.gene.com/download/pdf/xolair_prescribing.pdf.
  • Food and Drug Administration. Cinqair (reslizumab) highlights of prescribing information. 2019; https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0761033s010lbl.pdf.
  • Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809.
  • Holgate S, Casale T, Wenzel S, et al. Reisner C The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115(3):459–465.
  • Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312.
  • Frossing L, Silberbrandt A, Von Bulow A, et al. Airway gene expression identifies subtypes of type 2 inflammation in severe asthma. Clin Exp Allergy. 2021;52:59–69.
  • Organization WH Global health risks: mortality and burden of disease attributable to selected major risks. 2009; https://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf. Accessed May, 2021.
  • Backman H, Bhatta L, Hedman L, et al. Asthma is still a risk factor for mortality in Sweden and Norway – the nordic epilung study. Eur Respir J. 2019;54:A2778.
  • Lemmetyinen R, Karjalainen J, But A, et al. Higher mortality of adults with asthma: a 15‐year follow‐up of a population‐based cohort. Allergy. 2018;73(7):1479–1488.
  • Porsbjerg C, Ulrik C, Skjold T, et al. Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. Eur Clin Respir J. 2018;5(1):1440868.
  • Hekking PP, Amelink M, Wener RR, et al. Comorbidities in difficult-to-control asthma. J Allergy Clin Immunol Pract. 2018;6(1):108–113.
  • Toppila-Salmi S, Lemmetyinen R, Chanoine S, et al. Risk factors for severe adult-onset asthma: a multi-factor approach. BMC Pulm Med. 2021;21(1):214.
  • Erjefalt JS. Unravelling the complexity of tissue inflammation in uncontrolled and severe asthma. Curr Opin Pulm Med. 2019;25(1):79–86.
  • Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22–37.
  • Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858.
  • Janson C, Lisspers K, Stallberg B, et al. Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR). Eur Respir J. 2018;52(2):1701927.
  • Viinanen A, Lassenius MI, Toppila I, et al. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization. J Asthma. 2020;57(10):1092–1102.
  • Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659.
  • Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
  • Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556.
  • Schleich F, Graff S, Nekoee H, et al. Real-word experience with mepolizumab: does it deliver what it has promised? Clin Exp Allergy. 2020 Jun;50(6):687–695.
  • McDowell PJ, Diver S, Yang F, et al. Medical research council: refractory asthma stratification programme (RASP-UK consortium). The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir Med. 2021 Oct;9(10):1174–1184.
  • Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400.
  • Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
  • Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–798.
  • Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127.
  • Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366.
  • Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810.
  • FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141.
  • Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458.
  • Nair P, Bardin P, Humbert M, et al. Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma. J Allergy Clin Immunol Pract. 2020;8(2):555–564.
  • Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33(9):1605–1613.
  • Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
  • Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316.
  • Kostikas K, Brindicci C, Patalano F. Blood Eosinophils as biomarkers to drive treatment choices in asthma and COPD. Curr Drug Targets. 2018;19(16):1882–1896.
  • Kolmert J, Gomez C, Balgoma D, et al. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. A Clinical Observational Study. Am J Respir Crit Care Med. 2021;203(1):37–53.
  • Valentyna Yasinska JK, Zurita J, Quaranta A, et al. Mepolizumab decreases urinary excretion of LTE4 insevere asthma. Eur Respir J. 2020;56(Suppl. 64):2046.
  • Bood JR, Sundblad BM, Delin I, et al. Urinary excretion of lipid mediators in response to repeated eucapnic voluntary hyperpnea in asthmatic subjects. J Appl Physiol (1985). 2015;119(3):272–279.
  • Alobid I, Bernal-Sprekelsen M, Mullol J. Chronic rhinosinusitis and nasal polyps: the role of generic and specific questionnaires on assessing its impact on patient’s quality of life. Allergy. 2008;63(10):1267–1279.
  • Alobid I, Cardelus S, Benitez P, et al. Persistent asthma has an accumulative impact on the loss of smell in patients with nasal polyposis. Rhinology. 2011;49(5):519–524.
  • Kohli P, Naik AN, Harruff EE, et al. The prevalence of olfactory dysfunction in chronic rhinosinusitis. Laryngoscope. 2017;127(2):309–320.
  • Delemarre T, Holtappels G, De Ruyck N, et al. Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype. J Allergy Clin Immunol. 2020;146(2):337–343. e336.
  • McHugh T, Snidvongs K, Xie M, et al. High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta‐analysis. Int Forum Allergy Rhinol. 2018 Dec;8(12):1421–1429.
  • Vlaminck S, Vauterin T, Hellings PW, et al. The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study. Am J Rhinol Allergy. 2014;28(3):260–264.
  • Batra PS, Tong L, Citardi MJ. Analysis of comorbidities and objective parameters in refractory chronic rhinosinusitis. Laryngoscope. 2013;123(Suppl 7):S1–11.
  • Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947.
  • Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605.
  • Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9:1141–1153.
  • Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–1650.
  • Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double‐blind placebo‐controlled trial. Clin Exp Allergy. 2021;51:836–844.
  • Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The groupe d’Etudes et de Recherche sur les Maladies” Orphelines” Pulmonaires (GERM” O” P). Medicine (Baltimore). 1998;77(5):299–312.
  • Akuthota P, Weller PF. Eosinophilic pneumonias. Clin Microbiol Rev. 2012;25(4):649–660.
  • Nakahara Y, Hayashi S, Fukuno Y, et al. Increased interleukin-5 levels in bronchoalveolar lavage fluid is a major factor for eosinophil accumulation in acute eosinophilic pneumonia. Respiration. 2001;68(4):389–395.
  • Nakagome K, Nagata M. Possible mechanisms of eosinophil accumulation in eosinophilic pneumonia. Biomolecules. 2020;10(4):638.
  • Katoh S, Matsumoto N, Matsumoto K, et al. Elevated interleukin‐18 levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy. 2004;59(8):850–856.
  • Crowe M, Robinson D, Sagar M, et al. Chronic eosinophilic pneumonia: clinical perspectives. Ther Clin Risk Manag. 2019;15:397.
  • Marchand E, Cordier J-F Idiopathic chronic eosinophilic pneumonia. Paper presented at: Seminars in respiratory and critical care medicine 2006.
  • Brenard E, Pilette C, Dahlqvist C, et al. Real-Life study of mepolizumab in idiopathic chronic eosinophilic pneumonia. Lung. 2020;198(2):355–360.
  • Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48(5):1429–1441.
  • Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68(4):430–436.
  • Mahr A, Moosig F, Neumann T, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol. 2014;26(1):16–23.
  • Greco A, Rizzo MI, De Virgilio A, et al. Churg-Strauss syndrome. Autoimmun Rev. 2015;14(4):341–348.
  • Baldini C, Talarico R, Della Rossa A, et al. Clinical manifestations and treatment of Churg-Strauss syndrome. Rheum Dis Clin North Am. 2010;36(3):527–543.
  • Saku A, Furuta S, Hiraguri M, et al. Longterm outcomes of 188 Japanese patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol. 2018;45(8):1159–1166.
  • Lyons PA, Peters JE, Alberici F, et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun. 2019;10(1):5120.
  • Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014;10(8):474–483.
  • Manka LA, Guntur VP, Denson JL, et al. Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol. 2021;126(6):696–701 e691.
  • Martinez-Rivera C, Garcia-Olive I, Urrutia-Royo B, et al. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis. BMC Pulm Med. 2021;21(1):35.
  • Coppola A, Flores KR, De Filippis F. Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis. Respir Med Case Rep. 2020;30:101050.
  • Nanzer AM, Dhariwal J, Kavanagh J, et al. Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020;6(4):00451–2020.
  • Guntur VP, Manka LA, Denson JL, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2021;9(3):1186–1193 e1181.
  • Padoan R, Bianchi FC, Marchi MR, et al. Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2020;8(9):3225–3227. e3222.
  • Takenaka K, Minami T, Yoshihashi Y, et al. Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis. Allergol Int. 2019;68(4):539–540.
  • Butt NM, Lambert J, Ali S, et al. Guideline for the investigation and management of eosinophilia. Br J Haematol. 2017;176(4):553–572.
  • Valent P, Klion AD, Horny H-P, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612. e609.
  • Kahn JE, Groh M, Lefèvre G. (A critical appraisal of) classification of hypereosinophilic disorders. Front Med (Lausanne). 2017;4:216.
  • Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117(6):1292–1302.
  • Moller D, Tan J, Gauiran DTV, et al. Causes of hypereosinophilia in 100 consecutive patients. Eur J Haematol. 2020;105(3):292–301.
  • European Medicines Agency. Mepolizumab for the treatment of hypereosinophilic syndrome. 2010; https://www.ema.europa.eu/en/documents/orphan-designation/eu/3/04/213-public-summary-positive-opinion-orphan-designation-mepolizumab-treatment-hypereosinophilic_en.pdf. cited Mar 2021.
  • Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet J Rare Dis. 2007;2(1):1–12.
  • Curtis C, Ogbogu P. Hypereosinophilic syndrome. Clin Rev Allergy Immunol. 2016;50(2):240–251.
  • Khoury P, Abiodun AO, Holland-Thomas N, et al. Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids. J Allergy Clin Immunol. 2018;6(1):190–195.
  • Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124(6):1319–1325. e1313.
  • US National Library of Medicine. A phase 3 study to evaluate the efficacy and safety of benralizumab in patients with Hypereosinophilic Syndrome (HES) (NATRON). 2021; https://clinicaltrials.gov/ct2/show/NCT04191304. cited Jul, 2021.
  • Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397–1405.
  • Hansen S, Hilberg O, Ulrik CS, et al. The Danish severe asthma register: an electronic platform for severe asthma management and research. Eur Clin Respir J. 2020;8(1):1842117.
  • Stridsman C, Konradsen JR, Vanfleteren L, et al. The Swedish National Airway Register (SNAR) development, design and utility to date. Eur Clin Respir J. 2020;7(1):1833412.
  • The Nordic Severe Asthma Network. 2021; https://nordstar-nsan.com/. cited 2021 Jun 29.
  • Kankaanranta H, Ilmarinen P, Kankaanranta T, et al. Seinajoki Adult Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialised care. NPJ Prim Care Respir Med. 2015;25:15042.
  • Geale K, Darabi H, Lindh M, et al. NORDSTAR: paving the way for a new era in asthma research. Eur Respir J. 2020;55(4):1902476.
  • Andersen CL, Siersma VD, Hasselbalch HC, et al. Association of the blood eosinophil count with hematological malignancies and mortality. Am J Hematol. 2015;90(3):225–229.
  • Bjerrum OW, Siersma V, Hasselbalch HC, et al. Association of the blood eosinophil count with end-organ symptoms. Ann Med Surg (Lond). 2019;45:11–18.
  • Mogensen I, Alving K, Jacinto T, et al. Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12. Clin Exp Allergy. 2018;48(8):935–943.
  • Jansson SA, Backman H, Andersson M, et al. Severe asthma is related to high societal costs and decreased health related quality of life. Respir Med. 2020;162:105860.
  • Ilmarinen P, Tuomisto LE, Niemela O, et al. Prevalence of patients eligible for anti-il-5 treatment in a cohort of adult-onset asthma. J Allergy Clin Immunol Pract. 2019;7(1):165–174 e164.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.